Celldex Therapeutics, Inc.
CLDXDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
3 upcoming, 2 past
Temozolomide
Glioblastoma
barzolvolimab
Prurigo Nodularis
Rindopepimut (CDX-110) with GM-CSF
Glioblastoma
CDX-110 with GM-CSF
Malignant Glioma
"Investigator's Choice" chemotherapy
Breast Cancer
CDX-011
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Advanced Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Temozolomide | Phase 3 | Glioblastoma | - | - |
barzolvolimab | Phase 3 | Prurigo Nodularis | - | - |
Rindopepimut (CDX-110) with GM-CSF | Phase 2 | Glioblastoma | - | - |
CDX-110 with GM-CSF | Phase 2 | Malignant Glioma | - | - |
"Investigator's Choice" chemotherapy | Phase 2 | Breast Cancer | - | - |
CDX-011 | Phase 2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | - | - |
CDX-1401 in combination with Resiquimod and/or Poly-ICLC | Phase 2 | Advanced Malignancies | - | - |